Fulcrum therapeutics strengthens leadership team with the appointments of isabel kalofonos as chief commercial officer and heather faulds as chief regulatory affairs & quality assurance officer

Cambridge, mass., aug. 19, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (fulcrum) (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of isabel kalofonos as chief commercial officer and heather faulds as chief regulatory affairs & quality assurance officer. together, ms. kalofonos and ms. faulds will be instrumental in advancing losmapimod towards a new drug application (nda) submission and preparing for commercial launch.
FULC Ratings Summary
FULC Quant Ranking